Deerfield Management Company, L.P. (Series C) Protagonist Therapeutics, Inc Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $27.4 Million - $42.3 Million	-1,172,943 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $3.9 Million - $8.2 Million	-221,057 Reduced 15.86%	1,172,943 $40.1 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $404,169 - $1.55 Million	31,210 Added 2.29%	1,394,000 $24.7 Million
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $2.66 Million - $4.67 Million	104,000 Added 8.26%	1,362,790 $61.2 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $2.3 Million - $3.77 Million	-121,181 Reduced 8.78%	1,258,790 $32.6 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $3.7 Million - $5.03 Million	200,000 Added 16.95%	1,379,971 $27.8 Million
Q3 2020 Nov 16, 2020	BUY	$15.19 - $22.4 $2.53 Million - $3.73 Million	166,476 Added 16.43%	1,179,971 $23.1 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $6.27 Million - $19.1 Million	1,013,495 New	1,013,495 $17.9 Million
Q1 2018 May 15, 2018	SELL	$8.46 - $23.08 $1.9 Million - $5.19 Million	-225,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $3.26 Million - $4.68 Million	225,000	225,000 $4.68 Million

Others Institutions Holding PTGX

# of Institutions

212

Shares Held

59.1M

Call Options Held

19K

Put Options Held

107K

Farallon Capital Management LLC San Francisco, CA

5.84M
Shares

$268 Million
0.98% of portfolio
Black Rock Inc. New York, NY

5.76M
Shares

$264 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.29M
Shares

$242 Million
3.06% of portfolio
Bvf Inc San Francisco, CA

3.32M
Shares

$152 Million
3.52% of portfolio
Vanguard Group Inc Valley Forge, PA

3.24M
Shares

$149 Million
0.0% of portfolio

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account